Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Akseli Hemminki
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Living Beings
Procedures
Chemicals & Drugs
Disorders
Physiology
Anatomy
Devices
Sign-in to see full Profile
Network (preview)
44
Kanerva, Anna
40
Curiel, David
26
Hakkarainen, Tanja
23
Alvarez, Ronald
22
Bauerschmitz, Gerd
22
Desmond, Renee
18
Siegal, Gene
17
Wang, Minghui
15
Barnes, Mack
15
Aaltonen, Lauri
13
Järvinen, Heikki
11
Raki, Mari
11
Salovaara, Reijo
11
Särkioja, Merja
10
Ranki, Tuuli
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Akseli Hemminki (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Rajecki Maria; af Hällström Taija; Hakkarainen Tanja; Nokisalmi Petri; Hautaniemi Sampsa; Nieminen Anni I; Tenhunen Mikko; Rantanen Ville; Desmond Reneé A; Chen Dung-Tsa; Guse Kilian; Stenman Ulf-Håkan; Gargini Ricardo; Kapanen Mika; Klefström Juha; Kanerva Anna; Pesonen Sari; Ahtiainen Laura; Hemminki Akseli
Mre11 inhibition by oncolytic adenovirus associates with autophagy and underlies synergy with ionizing radiation.
International journal of cancer. Journal international du cancer 2009;125(10):2441-9.
-
2009: Koski Anniina; Rajecki Maria; Guse Kilian; Kanerva Anna; Ristimäki Ari; Pesonen Sari; Escutenaire Sophie; Hemminki Akseli
Systemic adenoviral gene delivery to orthotopic murine breast tumors with ablation of coagulation factors, thrombocytes and Kupffer cells.
The journal of gene medicine 2009;11(11):966-77.
-
2009: Bayo-Puxan Neus; Gimenez-Alejandre Marta; Lavilla-Alonso Sergio; Gros Alena; Cascallo Manel; Hemminki Akseli; Alemany Ramon
Replacement of adenovirus type 5 fiber shaft heparan sulfate proteoglycan-binding domain with RGD for improved tumor infectivity and targeting.
Human gene therapy 2009;20(10):1214-21.
-
2009: Hakkarainen Tanja; Rajecki Maria; Sarparanta Mirkka; Tenhunen Mikko; Airaksinen Anu J; Desmond Renée A; Kairemo Kalevi; Hemminki Akseli
Targeted radiotherapy for prostate cancer with an oncolytic adenovirus coding for human sodium iodide symporter.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(17):5396-403.
-
2009: Guse K; Diaconu I; Rajecki M; Sloniecka M; Hakkarainen T; Ristimäki A; Kanerva A; Pesonen S; Hemminki A
Ad5/3-9HIF-Delta24-VEGFR-1-Ig, an infectivity enhanced, dual-targeted and antiangiogenic oncolytic adenovirus for kidney cancer treatment.
Gene therapy 2009;16(8):1009-20.
-
2009: Matthews Kellie; Noker Patricia E; Tian Baohong; Grimes Sheila D; Fulton Ronna; Schweikart Karen; Harris Raymond; Aurigemma Rose; Wang Minghui; Barnes Mack N; Siegal Gene P; Hemminki Akseli; Zinn Kurt; Curiel David T; Alvarez Ronald D
Identifying the safety profile of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in anticipation of a phase I clinical trial in patients with recurrent ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(12):4131-7.
-
2009: Strauss Robert; Sova Pavel; Liu Ying; Li Zong Yi; Tuve Sebastian; Pritchard David; Brinkkoetter Paul; Möller Thomas; Wildner Oliver; Pesonen Sari; Hemminki Akseli; Urban Nicole; Drescher Charles; Lieber André
Epithelial phenotype confers resistance of ovarian cancer cells to oncolytic adenoviruses.
Cancer research 2009;69(12):5115-25.
-
2009: Diaconu Iulia; Denby Laura; Pesonen Sari; Cerullo Vincenzo; Bauerschmitz Gerd J; Guse Kilian; Rajecki Maria; Dias João D; Taari Kimmo; Kanerva Anna; Baker Andrew H; Hemminki Akseli
Serotype chimeric and fiber-mutated adenovirus Ad5/19p-HIT for targeting renal cancer and untargeting the liver.
Human gene therapy 2009;20(6):611-20.
-
2009: Kangasniemi L; Koskinen M; Jokinen M; Toriseva M; Ala-Aho R; Kähäri V-M; Jalonen H; Ylä-Herttuala S; Moilanen H; Stenman U-H; Diaconu I; Kanerva A; Pesonen S; Hakkarainen T; Hemminki A
Extended release of adenovirus from silica implants in vitro and in vivo.
Gene therapy 2009;16(1):103-10.
-
2008: Ylösmäki Erkko; Hakkarainen Tanja; Hemminki Akseli; Visakorpi Tapio; Andino Raul; Saksela Kalle
Generation of a conditionally replicating adenovirus based on targeted destruction of E1A mRNA by a cell type-specific MicroRNA.
Journal of virology 2008;82(22):11009-15.
-
2008: Bauerschmitz Gerd J; Ranki Tuuli; Kangasniemi Lotta; Ribacka Camilla; Eriksson Minna; Porten Marius; Herrmann Isabell; Ristimäki Ari; Virkkunen Pekka; Tarkkanen Maija; Hakkarainen Tanja; Kanerva Anna; Rein Daniel; Pesonen Sari; Hemminki Akseli
Tissue-specific promoters active in CD44+CD24-/low breast cancer cells.
Cancer research 2008;68(14):5533-9.
-
2008: Särkioja Merja; Hakkarainen Tanja; Eriksson Minna; Ristimäki Ari; Desmond Renee A; Kanerva Anna; Hemminki Akseli
The cyclo-oxygenase 2 promoter is induced in nontarget cells following adenovirus infection, but an AU-rich 3'-untranslated region destabilization element can increase specificity.
The journal of gene medicine 2008;10(7):744-53.
-
2008: Särkioja M; Pesonen S; Raki M; Hakkarainen T; Salo J; Ahonen M T; Kanerva A; Hemminki A
Changing the adenovirus fiber for retaining gene delivery efficacy in the presence of neutralizing antibodies.
Gene therapy 2008;15(12):921-9.
-
2008: Ribacka Camilla; Hemminki Akseli
Virotherapy as an approach against cancer stem cells.
Current gene therapy 2008;8(2):88-96.
-
2008: Raki Mari; Särkioja Merja; Desmond Renee A; Chen Dung-Tsa; Bützow Ralf; Hemminki Akseli; Kanerva Anna
Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer.
Gynecologic oncology 2008;108(1):166-72.
-
2008: Kanerva Anna; Lavilla-Alonso Sergio; Raki Mari; Kangasniemi Lotta; Bauerschmitz Gerd J; Takayama Koichi; Ristimäki Ari; Desmond Renee A; Hemminki Akseli
Systemic therapy for cervical cancer with potentially regulatable oncolytic adenoviruses.
PloS one 2008;3(8):e2917.
-
2008: Ribacka Camilla; Pesonen Sari; Hemminki Akseli
Cancer, stem cells, and oncolytic viruses.
Annals of medicine 2008;40(7):496-505.
-
2007: Eriksson Minna; Guse Kilian; Bauerschmitz Gerd; Virkkunen Pekka; Tarkkanen Maija; Tanner Minna; Hakkarainen Tanja; Kanerva Anna; Desmond Renee A; Pesonen Sari; Hemminki Akseli
Oncolytic adenoviruses kill breast cancer initiating CD44+CD24-/low cells.
Molecular therapy : the journal of the American Society of Gene Therapy 2007;15(12):2088-93.
-
2007: Paju Annukka; Hotakainen Kristina; Cao Yue; Laurila Timo; Gadaleanu Virgil; Hemminki Akseli; Stenman Ulf-Håkan; Bjartell Anders
Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells.
European urology 2007;52(6):1670-9.
-
2007: Guse Kilian; Ranki Tuuli; Ala-Opas Martti; Bono Petri; Särkioja Merja; Rajecki Maria; Kanerva Anna; Hakkarainen Tanja; Hemminki Akseli
Treatment of metastatic renal cancer with capsid-modified oncolytic adenoviruses.
Molecular cancer therapeutics 2007;6(10):2728-36.
-
2007: Raki M; Hakkarainen T; Bauerschmitz G J; Särkioja M; Desmond R A; Kanerva A; Hemminki A
Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirus.
Gene therapy 2007;14(19):1380-8.
-
2007: Kanerva Anna; Raki Mari; Hemminki Akseli
Gene therapy of gynaecological diseases.
Expert opinion on biological therapy 2007;7(9):1347-61.
-
2007: Hakkarainen Tanja; Särkioja Merja; Lehenkari Petri; Miettinen Susanna; Ylikomi Timo; Suuronen Riitta; Desmond Renee A; Kanerva Anna; Hemminki Akseli
Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors.
Human gene therapy 2007;18(7):627-41.
-
2007: Ranki Tuuli; Särkioja Merja; Hakkarainen Tanja; von Smitten Karl; Kanerva Anna; Hemminki Akseli
Systemic efficacy of oncolytic adenoviruses in imagable orthotopic models of hormone refractory metastatic breast cancer.
International journal of cancer. Journal international du cancer 2007;121(1):165-74.
-
2007: Guse K; Dias J D; Bauerschmitz G J; Hakkarainen T; Aavik E; Ranki T; Pisto T; Särkioja M; Desmond R A; Kanerva A; Hemminki A
Luciferase imaging for evaluation of oncolytic adenovirus replication in vivo.
Gene therapy 2007;14(11):902-11.
-
2007: Lam J T; Hemminki A; Kanerva A; Lee K B; Blackwell J L; Desmond R; Siegal G P; Curiel D T
A three-dimensional assay for measurement of viral-induced oncolysis.
Cancer gene therapy 2007;14(4):421-30.
-
2007: Rajecki Maria; Kanerva Anna; Stenman Ulf-Håkan; Tenhunen Mikko; Kangasniemi Lotta; Särkioja Merja; Ala-Opas Martti Y; Alfthan Henrik; Sankila Anna; Rintala Erkki; Desmond Renee A; Hakkarainen Tanja; Hemminki Akseli
Treatment of prostate cancer with Ad5/3Delta24hCG allows non-invasive detection of the magnitude and persistence of virus replication in vivo.
Molecular cancer therapeutics 2007;6(2):742-51.
-
2007: Kanerva Anna; Raki Mari; Ranki Tuuli; Särkioja Merja; Koponen Jarmo; Desmond Renee A; Helin Aija; Stenman Ulf-Håkan; Isoniemi Helena; Höckerstedt Krister; Ristimäki Ari; Hemminki Akseli
Chlorpromazine and apigenin reduce adenovirus replication and decrease replication associated toxicity.
The journal of gene medicine 2007;9(1):3-9.
-
2007: Ranki T; Kanerva A; Ristimäki A; Hakkarainen T; Särkioja M; Kangasniemi L; Raki M; Laakkonen P; Goodison S; Hemminki A
A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer.
Gene therapy 2007;14(1):58-67.
-
2006: Shi Wenfang; Hemminki Akseli; Bartlett Jeffrey S
Capsid modifications overcome low heterogeneous expression of heparan sulfate proteoglycan that limits AAV2-mediated gene transfer and therapeutic efficacy in human ovarian carcinoma.
Gynecologic oncology 2006;103(3):1054-62.
-
2006: Hakkarainen Tanja; Hemminki Akseli; Curiel David T; Wahlfors Jarmo
A conditionally replicative adenovirus that codes for a TK-GFP fusion protein (Ad5Delta24TK-GFP) for evaluation of the potency of oncolytic virotherapy combined with molecular chemotherapy.
International journal of molecular medicine 2006;18(4):751-9.
-
2006: Sarkioja Merja; Kanerva Anna; Salo Jarmo; Kangasniemi Lotta; Eriksson Minna; Raki Mari; Ranki Tuuli; Hakkarainen Tanja; Hemminki Akseli
Noninvasive imaging for evaluation of the systemic delivery of capsid-modified adenoviruses in an orthotopic model of advanced lung cancer.
Cancer 2006;107(7):1578-88.
-
2006: Raki Mari; Rein Daniel T; Kanerva Anna; Hemminki Akseli
Gene transfer approaches for gynecological diseases.
Molecular therapy : the journal of the American Society of Gene Therapy 2006;14(2):154-63.
-
2006: Bauerschmitz Gerd J; Guse Kilian; Kanerva Anna; Menzel Artur; Herrmann Isabell; Desmond Renee A; Yamamoto Masato; Nettelbeck Dirk M; Hakkarainen Tanja; Dall Peter; Curiel David T; Hemminki Akseli
Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells.
Molecular therapy : the journal of the American Society of Gene Therapy 2006;14(2):164-74.
-
2006: Kangasniemi Lotta; Kiviluoto Tuula; Kanerva Anna; Raki Mari; Ranki Tuuli; Sarkioja Merja; Wu Hongju; Marini Frank; Höckerstedt Krister; Isoniemi Helena; Alfthan Henrik; Stenman Ulf-Håkan; Curiel David T; Hemminki Akseli
Infectivity-enhanced adenoviruses deliver efficacy in clinical samples and orthotopic models of disseminated gastric cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(10):3137-44.
-
2006: Hemminki Akseli; Kellokumpu-Lehtinen Pirkko-Liisa
Harmful impact of EU clinical trials directive.
BMJ (Clinical research ed.) 2006;332(7540):501-2.
-
2006: Joensuu Heikki; Kellokumpu-Lehtinen Pirkko-Liisa; Bono Petri; Alanko Tuomo; Kataja Vesa; Asola Raija; Utriainen Tapio; Kokko Riitta; Hemminki Akseli; Tarkkanen Maija; Turpeenniemi-Hujanen Taina; Jyrkkiö Sirkku; Flander Martti; Helle Leena; Ingalsuo Seija; Johansson Kaisu; Jääskeläinen Anna-Stina; Pajunen Marjo; Rauhala Mervi; Kaleva-Kerola Jaana; Salminen Tapio; Leinonen Mika; Elomaa Inkeri; Isola Jorma;
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.
The New England journal of medicine 2006;354(8):809-20.
-
2005: Alhopuro Pia; Alazzouzi Hafid; Sammalkorpi Heli; Dávalos Verónica; Salovaara Reijo; Hemminki Akseli; Järvinen Heikki; Mecklin Jukka-Pekka; Schwartz Simo; Aaltonen Lauri A; Arango Diego
SMAD4 levels and response to 5-fluorouracil in colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(17):6311-6.
-
2005: Arango Diego; Laiho Paivi; Kokko Antti; Alhopuro Pia; Sammalkorpi Heli; Salovaara Reijo; Nicorici Daniel; Hautaniemi Sampsa; Alazzouzi Hafid; Mecklin Jukka-Pekka; Järvinen Heikki; Hemminki Akseli; Astola Jaakko; Schwartz Simo; Aaltonen Lauri A
Gene-expression profiling predicts recurrence in Dukes' C colorectal cancer.
Gastroenterology 2005;129(3):874-84.
-
2005: Raki M; Kanerva A; Ristimaki A; Desmond R A; Chen D-T; Ranki T; Sarkioja M; Kangasniemi L; Hemminki A
Combination of gemcitabine and Ad5/3-Delta24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer.
Gene therapy 2005;12(15):1198-205.
-
2005: Hakkarainen Tanja; Wahlfors Tiina; Meriläinen Outi; Loimas Sami; Hemminki Akseli; Wahlfors Jarmo
VP22 does not significantly enhance enzyme prodrug cancer gene therapy as a part of a VP22-HSVTk-GFP triple fusion construct.
The journal of gene medicine 2005;7(7):898-907.
-
2005: Alazzouzi Hafid; Alhopuro Pia; Salovaara Reijo; Sammalkorpi Heli; Järvinen Heikki; Mecklin Jukka-Pekka; Hemminki Akeseli; Schwartz Simo; Aaltonen Lauri A; Arango Diego
SMAD4 as a prognostic marker in colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(7):2606-11.
-
2005: Rein Daniel T; Breidenbach Martina; Kirby Tyler O; Han Tie; Siegal Gene P; Bauerschmitz Gerd J; Wang Minghui; Nettelbeck Dirk M; Tsuruta Yuko; Yamamoto Masato; Dall Peter; Hemminki Akseli; Curiel David T
A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(3):1327-35.
-
2005: Wang Minghui; Hemminki Akseli; Siegal Gene P; Barnes Mack N; Dmitriev Igor; Krasnykh Victor; Liu Bin; Curiel David T; Alvarez Ronald D
Adenoviruses with an RGD-4C modification of the fiber knob elicit a neutralizing antibody response but continue to allow enhanced gene delivery.
Gynecologic oncology 2005;96(2):341-8.
-
2005: Kanerva A; Zinn K R; Peng K-W; Ranki T; Kangasniemi L; Chaudhuri T R; Desmond R A; Wang M; Takayama K; Hakkarainen T; Alfthan H; Stenman U-H; Curiel D T; Hemminki A
Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus.
Gene therapy 2005;12(1):87-94.
-
2005: Hakkarainen Tanja; Kanerva Anna; Hemminki Akseli
[Adenoviruses in cancer therapy]
Duodecim; lääketieteellinen aikakauskirja 2005;121(20):2195-203.
-
2005: Kanerva Anna; Hemminki Akseli
Adenoviruses for treatment of cancer.
Annals of medicine 2005;37(1):33-43.
-
2004: Lam John T; Kanerva Anna; Bauerschmitz Gerd J; Takayama Koichi; Suzuki Kaori; Yamamoto Masato; Bhoola Snehal M; Liu Bin; Wang Minghui; Barnes Mack N; Alvarez Ronald D; Siegal Gene P; Curiel David T; Hemminki Akseli
Inter-patient variation in efficacy of five oncolytic adenovirus candidates for ovarian cancer therapy.
The journal of gene medicine 2004;6(12):1333-42.
-
2004: Rein Daniel T; Breidenbach Martina; Nettelbeck Dirk M; Kawakami Yosuke; Siegal Gene P; Huh Warner K; Wang Minghui; Hemminki Akseli; Bauerschmitz Gerd J; Yamamoto Masato; Adachi Yasuo; Takayama Koichi; Dall Peter; Curiel David T
Evaluation of tissue-specific promoters in carcinomas of the cervix uteri.
The journal of gene medicine 2004;6(11):1281-9.
-
2004: Lamfers Martine L M; Hemminki Akseli
Multicellular tumor spheroids in gene therapy and oncolytic virus therapy.
Current opinion in molecular therapeutics 2004;6(4):403-11.
-
2004: Bauerschmitz G J; Hemminki A; Curiel D T; Dall P
[Tumour-dependent replicating adenoviruses in the treatment of carcinomas]
Zentralblatt für Gynäkologie 2004;126(4):280-1.
-
2004: Bauerschmitz Gerd J; Kanerva Anna; Wang Minghui; Herrmann Isabell; Shaw Denise R; Strong Theresa V; Desmond Renee; Rein Daniel T; Dall Peter; Curiel David T; Hemminki Akseli
Evaluation of a selectively oncolytic adenovirus for local and systemic treatment of cervical cancer.
International journal of cancer. Journal international du cancer 2004;111(2):303-9.
-
2004: Kanerva Anna; Hemminki Akseli
Modified adenoviruses for cancer gene therapy.
International journal of cancer. Journal international du cancer 2004;110(4):475-80.
-
2004: Glasgow Joel N; Kremer Eric J; Hemminki Akseli; Siegal Gene P; Douglas Joanne T; Curiel David T
An adenovirus vector with a chimeric fiber derived from canine adenovirus type 2 displays novel tropism.
Virology 2004;324(1):103-16.
-
2004: Saukkonen Kirsi; Hemminki Akseli
Tissue-specific promoters for cancer gene therapy.
Expert opinion on biological therapy 2004;4(5):683-96.
-
2004: Breidenbach Martina; Rein Daniel T; Wang Minghui; Nettelbeck Dirk M; Hemminki Akseli; Ulasov Ilya; Rivera Angel R; Everts Maaike; Alvarez Ronald D; Douglas Joanne T; Curiel David T
Genetic replacement of the adenovirus shaft fiber reduces liver tropism in ovarian cancer gene therapy.
Human gene therapy 2004;15(5):509-18.
-
2004: Glasgow J N; Bauerschmitz G J; Curiel D T; Hemminki A
Transductional and transcriptional targeting of adenovirus for clinical applications.
Current gene therapy 2004;4(1):1-14.
-
2004: Kanerva A; Bauerschmitz G J; Yamamoto M; Lam J T; Alvarez R D; Siegal G P; Curiel D T; Hemminki A
A cyclooxygenase-2 promoter-based conditionally replicating adenovirus with enhanced infectivity for treatment of ovarian adenocarcinoma.
Gene therapy 2004;11(6):552-9.
-
2004: Verwijnen Suzanne M; Sillevis Smith Peter A E; Hoeben Rob C; Rabelink Martin J W E; Wiebe Leonard; Curiel David T; Hemminki Akseli; Krenning Eric P; de Jong Marion
Molecular imaging and treatment of malignant gliomas following adenoviral transfer of the herpes simplex virus-thymidine kinase gene and the somatostatin receptor subtype 2 gene.
Cancer biotherapy & radiopharmaceuticals 2004;19(1):111-20.
-
2003: Kanerva Anna; Zinn Kurt R; Chaudhuri Tandra R; Lam John T; Suzuki Kaori; Uil Taco G; Hakkarainen Tanja; Bauerschmitz Gerd J; Wang Minghui; Liu Bin; Cao Zhihong; Alvarez Ronald D; Curiel David T; Hemminki Akseli
Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus.
Molecular therapy : the journal of the American Society of Gene Therapy 2003;8(3):449-58.
-
2003: Hemminki Akseli; Wang Minghui; Hakkarainen Tanja; Desmond Renee A; Wahlfors Jarmo; Curiel David T
Production of an EGFR targeting molecule from a conditionally replicating adenovirus impairs its oncolytic potential.
Cancer gene therapy 2003;10(8):583-8.
-
2003: Barker S D; Dmitriev I P; Nettelbeck D M; Liu B; Rivera A A; Alvarez R D; Curiel D T; Hemminki A
Combined transcriptional and transductional targeting improves the specificity and efficacy of adenoviral gene delivery to ovarian carcinoma.
Gene therapy 2003;10(14):1198-204.
-
2003: Lam John T; Bauerschmitz Gerd J; Kanerva Anna; Barker Shannon D; Straughn J Michael; Wang Minghui; Barnes Mack N; Blackwell Jerry L; Siegal Gene P; Alvarez Ronald D; Curiel David T; Hemminki Akseli
Replication of an integrin targeted conditionally replicating adenovirus on primary ovarian cancer spheroids.
Cancer gene therapy 2003;10(5):377-87.
-
2003: Curiel Tyler J; Wei Shuang; Dong Haidong; Alvarez Xavier; Cheng Pui; Mottram Peter; Krzysiek Roman; Knutson Keith L; Daniel Ben; Zimmermann Maria Carla; David Odile; Burow Matthew; Gordon Alan; Dhurandhar Nina; Myers Leann; Berggren Ruth; Hemminki Akseli; Alvarez Ronald D; Emilie Dominique; Curiel David T; Chen Lieping; Zou Weiping
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity.
Nature medicine 2003;9(5):562-7.
-
2003: Barker Shannon D; Coolidge Candace J; Kanerva Anna; Hakkarainen Tanja; Yamamoto Masato; Liu Bin; Rivera Angel A; Bhoola Snehal M; Barnes Mack N; Alvarez Ronald D; Curiel David T; Hemminki Akseli
The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy.
The journal of gene medicine 2003;5(4):300-10.
-
2003: Röder Gernot; Keil Oliver; Prisack Hans-Bernd; Bauerschmitz Gerd; Hanstein Bettina; Nestle-Krämling Caroline; Hemminki Akseli; Bender Hans-Georg; Niederacher Dieter; Dall Peter
Novel cGMP liposomal vectors mediate efficient gene transfer.
Cancer gene therapy 2003;10(4):312-7.
-
2003: Hemminki Akseli; Kanerva Anna; Kremer Eric J; Bauerschmitz Gerd J; Smith Bruce F; Liu Bin; Wang Minghui; Desmond Renee A; Keriel Anne; Barnett Brian; Baker Henry J; Siegal Gene P; Curiel David T
A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model.
Molecular therapy : the journal of the American Society of Gene Therapy 2003;7(2):163-73.
-
2003: Hemminki Akseli; Kanerva Anna; Liu Bin; Wang Minghui; Alvarez Ronald D; Siegal Gene P; Curiel David T
Modulation of coxsackie-adenovirus receptor expression for increased adenoviral transgene expression.
Cancer research 2003;63(4):847-53.
-
2003: Hakkarainen Tanja; Hemminki Akseli; Pereboev Alexander V; Barker Shannon D; Asiedu Clement K; Strong Theresa V; Kanerva Anna; Wahlfors Jarmo; Curiel David T
CD40 is expressed on ovarian cancer cells and can be utilized for targeting adenoviruses.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(2):619-24.
-
2002: Bauerschmitz Gerd J; Barker Shannon D; Hemminki Akseli
Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agents (review).
International journal of oncology 2002;21(6):1161-74.
-
2002: Hemminki Akseli; Wang Minghui; Desmond Renee A; Strong Theresa V; Alvarez Ronald D; Curiel David T
Serum and ascites neutralizing antibodies in ovarian cancer patients treated with intraperitoneal adenoviral gene therapy.
Human gene therapy 2002;13(12):1505-14.
-
2002: Haviv Yosef S; Blackwell Jerry L; Kanerva Anna; Nagi Peter; Krasnykh Victor; Dmitriev Igor; Wang Minghui; Naito Seiji; Lei Xiaosheng; Hemminki Akseli; Carey Delicia; Curiel David T
Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors.
Cancer research 2002;62(15):4273-81.
-
2002: Kanerva Anna; Wang Minghui; Bauerschmitz Gerd J; Lam John T; Desmond Renee A; Bhoola Snehal M; Barnes Mack N; Alvarez Ronald D; Siegal Gene P; Curiel David T; Hemminki Akseli
Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses.
Molecular therapy : the journal of the American Society of Gene Therapy 2002;5(6):695-704.
-
2002: Hemminki Akseli; Zinn Kurt R; Liu Bin; Chaudhuri Tandra R; Desmond Renee A; Rogers Buck E; Barnes Mack N; Alvarez Ronald D; Curiel David T
In vivo molecular chemotherapy and noninvasive imaging with an infectivity-enhanced adenovirus.
Journal of the National Cancer Institute 2002;94(10):741-9.
-
2002: Barnes Mack N; Coolidge Candace J; Hemminki Akseli; Alvarez Ronald D; Curiel David T
Conditionally replicative adenoviruses for ovarian cancer therapy.
Molecular cancer therapeutics 2002;1(6):435-9.
-
2002: Bauerschmitz Gerd J; Nettelbeck Dirk M; Kanerva Anna; Baker Andrew H; Hemminki Akseli; Reynolds Paul N; Curiel David T
The flt-1 promoter for transcriptional targeting of teratocarcinoma.
Cancer research 2002;62(5):1271-4.
-
2002: Bauerschmitz Gerd J; Lam John T; Kanerva Anna; Suzuki Kaori; Nettelbeck Dirk M; Dmitriev Igor; Krasnykh Victor; Mikheeva Galina V; Barnes Mack N; Alvarez Ronald D; Dall Peter; Alemany Ramon; Curiel David T; Hemminki Akseli
Treatment of ovarian cancer with a tropism modified oncolytic adenovirus.
Cancer research 2002;62(5):1266-70.
-
2002: Arafat W O; Gómez-Navarro J; Buchsbaum D J; Xiang J; Wang M; Casado E; Barker S D; Mahasreshti P J; Haisma H J; Barnes M N; Siegal G P; Alvarez R D; Hemminki A; Nettelbeck D M; Curiel D T
Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv.
Gene therapy 2002;9(4):256-62.
-
2002: Kanerva Anna; Mikheeva Galina V; Krasnykh Victor; Coolidge Candace J; Lam John T; Mahasreshti Parameshwar J; Barker Shannon D; Straughn Michael; Barnes Mack N; Alvarez Ronald D; Hemminki Akseli; Curiel David T
Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(1):275-80.
-
2002: Hemminki Akseli; Alvarez Ronald D
Adenoviruses in oncology: a viable option?
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 2002;16(2):77-87.
-
2001: Hemminki A; Belousova N; Zinn K R; Liu B; Wang M; Chaudhuri T R; Rogers B E; Buchsbaum D J; Siegal G P; Barnes M N; Gomez-Navarro J; Curiel D T; Alvarez R D
An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression.
Molecular therapy : the journal of the American Society of Gene Therapy 2001;4(3):223-31.
-
2001: Hemminki A; Dmitriev I; Liu B; Desmond R A; Alemany R; Curiel D T
Targeting oncolytic adenoviral agents to the epidermal growth factor pathway with a secretory fusion molecule.
Cancer research 2001;61(17):6377-81.
-
2001: Casado E; Nettelbeck D M; Gomez-Navarro J; Hemminki A; Gonzalez Baron M; Siegal G P; Barnes M N; Alvarez R D; Curiel D T
Transcriptional targeting for ovarian cancer gene therapy.
Gynecologic oncology 2001;82(2):229-37.
-
2001: Casado E; Gomez-Navarro J; Yamamoto M; Adachi Y; Coolidge C J; Arafat W O; Barker S D; Wang M H; Mahasreshti P J; Hemminki A; Gonzalez-Baron M; Barnes M N; Pustilnik T B; Siegal G P; Alvarez R D; Curiel D T
Strategies to accomplish targeted expression of transgenes in ovarian cancer for molecular therapeutic applications.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(8):2496-504.
-
2001: Mahasreshti P J; Navarro J G; Kataram M; Wang M H; Carey D; Siegal G P; Barnes M N; Nettelbeck D M; Alvarez R D; Hemminki A; Curiel D T
Adenovirus-mediated soluble FLT-1 gene therapy for ovarian carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(7):2057-66.
-
2001: Barker S D; Casado E; Gomez-Navarro J; Xiang J; Arafat W; Mahasreshti P; Pustilnik T B; Hemminki A; Siegal G P; Alvarez R D; Curiel D T
An immunomagnetic-based method for the purification of ovarian cancer cells from patient-derived ascites.
Gynecologic oncology 2001;82(1):57-63.
-
2000: Hemminki A; Mecklin J P; Järvinen H; Aaltonen L A; Joensuu H
Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy.
Gastroenterology 2000;119(4):921-8.
-
1999: Roth S; Sistonen P; Salovaara R; Hemminki A; Loukola A; Johansson M; Avizienyte E; Cleary K A; Lynch P; Amos C I; Kristo P; Mecklin J P; Kellokumpu I; Järvinen H; Aaltonen L A
SMAD genes in juvenile polyposis.
Genes, chromosomes & cancer 1999;26(1):54-61.
-
1999: Hemminki A
The molecular basis and clinical aspects of Peutz-Jeghers syndrome.
Cellular and molecular life sciences : CMLS 1999;55(5):735-50.
-
1999: Avizienyte E; Loukola A; Roth S; Hemminki A; Tarkkanen M; Salovaara R; Arola J; Bützow R; Husgafvel-Pursiainen K; Kokkola A; Järvinen H; Aaltonen L A
LKB1 somatic mutations in sporadic tumors.
The American journal of pathology 1999;154(3):677-81.
-
1999: Ylikorkala A; Avizienyte E; Tomlinson I P; Tiainen M; Roth S; Loukola A; Hemminki A; Johansson M; Sistonen P; Markie D; Neale K; Phillips R; Zauber P; Twama T; Sampson J; Järvinen H; Mäkelä T P; Aaltonen L A
Mutations and impaired function of LKB1 in familial and non-familial Peutz-Jeghers syndrome and a sporadic testicular cancer.
Human molecular genetics 1999;8(1):45-51.
-
1998: Avizienyte E; Roth S; Loukola A; Hemminki A; Lothe R A; Stenwig A E; Fosså S D; Salovaara R; Aaltonen L A
Somatic mutations in LKB1 are rare in sporadic colorectal and testicular tumors.
Cancer research 1998;58(10):2087-90.
-
1998: Aaltonen L A; Salovaara R; Kristo P; Canzian F; Hemminki A; Peltomäki P; Chadwick R B; Kääriäinen H; Eskelinen M; Järvinen H; Mecklin J P; de la Chapelle A
Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease.
The New England journal of medicine 1998;338(21):1481-7.
-
1998: Olschwang S; Markie D; Seal S; Neale K; Phillips R; Cottrell S; Ellis I; Hodgson S; Zauber P; Spigelman A; Iwama T; Loff S; McKeown C; Marchese C; Sampson J; Davies S; Talbot I; Wyke J; Thomas G; Bodmer W; Hemminki A; Avizienyte E; de la Chapelle A; Aaltonen L; Tomlinson I
Peutz-Jeghers disease: most, but not all, families are compatible with linkage to 19p13.3.
Journal of medical genetics 1998;35(1):42-4.
-
1998: Hemminki A; Markie D; Tomlinson I; Avizienyte E; Roth S; Loukola A; Bignell G; Warren W; Aminoff M; Höglund P; Järvinen H; Kristo P; Pelin K; Ridanpää M; Salovaara R; Toro T; Bodmer W; Olschwang S; Olsen A S; Stratton M R; de la Chapelle A; Aaltonen L A
A serine/threonine kinase gene defective in Peutz-Jeghers syndrome.
Nature 1998;391(6663):184-7.
-
1998: Hemminki A; Avizienyte E; Roth S; Loukola A; Aaltonen L A; Järvinen H; de la Chapelle A
[A serine/threonine kinase gene defective in Peutz-Jeghers syndrome]
Duodecim; lääketieteellinen aikakauskirja 1998;114(7):667-8.
-
1998: Wolf M; Hemminki A; Kivioja A; Sistonen P; Kaitila I; Ervasti H; Kinnunen J; Karaharju E; Knuutila S
A novel splice site mutation of the EXT2 gene in a Finnish hereditary multiple exostoses family. Mutations in brief no. 197. Online.
Human mutation 1998;12(5):362.
-
1997: Marsh D J; Roth S; Lunetta K L; Hemminki A; Dahia P L; Sistonen P; Zheng Z; Caron S; van Orsouw N J; Bodmer W F; Cottrell S E; Dunlop M G; Eccles D; Hodgson S V; Järvinen H; Kellokumpu I; Markie D; Neale K; Phillips R; Rozen P; Syngal S; Vijg J; Tomlinson I P; Aaltonen L A; Eng C
Exclusion of PTEN and 10q22-24 as the susceptibility locus for juvenile polyposis syndrome.
Cancer research 1997;57(22):5017-21.
-
1997: Hemminki A; Tomlinson I; Markie D; Järvinen H; Sistonen P; Björkqvist A M; Knuutila S; Salovaara R; Bodmer W; Shibata D; de la Chapelle A; Aaltonen L A
Localization of a susceptibility locus for Peutz-Jeghers syndrome to 19p using comparative genomic hybridization and targeted linkage analysis.
Nature genetics 1997;15(1):87-90.
-
1996: Canzian F; Salovaara R; Hemminki A; Kristo P; Chadwick R B; Aaltonen L A; de la Chapelle A
Semiautomated assessment of loss of heterozygosity and replication error in tumors.
Cancer research 1996;56(14):3331-7.
-
1994: Hemminki A; Peltomäki P; Mecklin J P; Järvinen H; Salovaara R; Nyström-Lahti M; de la Chapelle A; Aaltonen L A
Loss of the wild type MLH1 gene is a feature of hereditary nonpolyposis colorectal cancer.
Nature genetics 1994;8(4):405-10.
Sign-in to see more
